Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Sijmen de Vries
|
| gptkbp:country |
gptkb:Netherlands
|
| gptkbp:focus |
rare diseases
|
| gptkbp:founded |
1988
|
| gptkbp:founder |
Bruno Giannetti
|
| gptkbp:headquarters_location |
gptkb:Leiden
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:Euronext_Amsterdam
|
| gptkbp:main_therapeutic_area |
gptkb:hereditary_hemorrhagic_telangiectasia
|
| gptkbp:market |
global
|
| gptkbp:notableProduct |
recombinant human C1 esterase inhibitor
|
| gptkbp:numberOfEmployees |
~300
|
| gptkbp:product |
gptkb:Ruconest
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
| gptkbp:stockExchange |
gptkb:Euronext_Amsterdam
|
| gptkbp:stockSymbol |
PHARM
|
| gptkbp:website |
https://www.pharming.com/
|
| gptkbp:bfsParent |
gptkb:Ruconest
|
| gptkbp:bfsLayer |
8
|
| http://www.w3.org/2000/01/rdf-schema#label |
Pharming Group NV
|